An investigator-initiated phase II study has been launched with SynAct Pharma's lead candidate, resomelagon, in patients with dengue in Brazil. This trial runs in parallel with the ongoing study in rheumatoid arthritis. BioStock spoke with the company's CSO, Thomas Jonassen, who sees strong potential for resomelagon in both RA and dengue, as well as other indications:
- We work behind the scenes to expand our pipeline and look forward to presenting the next program(s) once we are ready, says Jonassen.